Effect of Tumor-Derived TGF-Beta on the Efficacy of Dendritic Cell Vaccines
Abstract
As antigen presenting cells capable of inducing strong cytotoxic T lymphocyte (CTL) responses to specific antigens, dendritic cells (DCs) have become prime candidates for use in cancer immunotherapy. It has been shown that treatment of DCs with tumor cell supermatants results in reduced expression of MHC class II and reduced ability to induce a CTb response. These findings have led to the suggestion that tumors secrete soluble factors that inhibit the antigen presenting functions of DCs. In the clinical setting, immunization with DOs is well tolerated, but is unable to produce significant clinical responses. Taken together, these findings suggest that the tumors secrete immunosuppressive factors that interfere with the efficacy of DC immunotherapy. One such factor is transforming growth factor-% (TGF-P). TGF-% is a known suppressor of T cell function and recently has been implicated in decreasing the function of antigen presenting cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2003
- Accession Number
- ADA418005
Entities
People
- Emmanuel T. Akporiaye
- James J. Kobie
Organizations
- University of Arizona